Daytime pulsed dose rate brachytherapy as a new treatment option for previously irradiated patients with recurrent oesophageal cancer
Authors:
- W HarmsWHW Harms
- R KrempienRKR Krempien
- C GrehnCGC Grehn
- C BernsCBC Berns
- F W HensleyFHF W Hensley
- J DebusJDJ Debus
- 1 March 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 78 (927) , 236-241
Abstract
The aim of this study was to evaluate the feasibility, effects, and toxicity of pulsed dose rate (PDR) brachytherapy for re-irradiation of oesophageal carcinoma. A total of 16 patients (median age 67 years) with inoperable recurrences from oesophageal cancer after primary radio-(chemo)-therapy (median 50 Gy) were re-irradiated using PDR brachytherapy ((192)Ir, 37 GBq). Treatment was carried out on an outpatient basis applying a weekly 5 Gy daytime schedule (0.5 Gy pulse(-1) h(-1), total dose 15-20 Gy). The dose was prescribed 10 mm from the mid-dwell position and encompassed the clipped tumour extension with 2 cm margins. The use of clips for delineation of tumour extent and catheter movement during irradiations was evaluated. All 61 PDR treatments were applied safely. The median catheter movement was 5 mm, range 2-12 mm. After a median follow-up of 8 months, three patients had a complete and five a partial remission. Body weight increased in 5 of 16 (31%) and was stable in 4 of 16 (25%) patients, respectively. The median grade 2 (RTOG/EORTC) dysphagia-free survival was 17 months. Seven patients experienced grade 1, five grade 2, and one grade 3 late toxicity. Three patients with uncontrolled locoregional disease showed grade 4 complications (oesophago-tracheal fistulae (n=2), fatal arterial bleeding (n=1). Daytime PDR brachytherapy proved to be feasible and provided effective palliation. Toxicity remains a major problem. Thus, total dose should be restricted to <15 Gy in this palliative situation.Keywords
This publication has 14 references indexed in Scilit:
- Results of chest wall reirradiation using pulsed-dose-rate (PDR) brachytherapy molds for breast cancer local recurrencesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- Chemoradiotherapy of Locally Advanced Esophageal CancerJAMA, 1999
- Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagusInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal CancerNew England Journal of Medicine, 1998
- Die Strahlenbehandlung in der multimodalen Therapie des ÖsophaguskarzinomsStrahlentherapie und Onkologie, 1997
- American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer☆International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- Pulsed brachytherapy: The conditions for no significant loss of therapeutic ratio compared with traditional low dose rate brachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1992
- Conditions for the equivalence of continuous to pulsed low dose rate brachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1991
- Autopsy findings in 111 cases of esophageal cancerCancer, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958